Core Insights - AptarGroup reported revenue of $961.13 million for the quarter ended September 2025, marking a year-over-year increase of 5.7% and exceeding the Zacks Consensus Estimate by 0.91% [1] - The company's EPS for the same period was $1.62, up from $1.49 a year ago, with a surprise of 3.18% over the consensus estimate of $1.57 [1] Revenue Performance - Aptar Beauty generated net sales of $327.77 million, surpassing the average estimate of $309.91 million, reflecting an 8.2% year-over-year increase [4] - Aptar Closures reported net sales of $187.95 million, slightly below the average estimate of $190.73 million, with a year-over-year change of 1.1% [4] - Aptar Pharma achieved net sales of $445.41 million, closely aligning with the average estimate of $445.73 million, and showing a year-over-year increase of 5.9% [4] EBITDA Analysis - Adjusted EBITDA for Aptar Pharma was $165.77 million, exceeding the average estimate of $157.17 million [4] - Adjusted EBITDA for Aptar Closures was $30.34 million, below the average estimate of $32.49 million [4] - Corporate & Other reported an adjusted EBITDA of -$13.26 million, better than the average estimate of -$19.22 million [4] - Adjusted EBITDA for Aptar Beauty was $39.75 million, falling short of the average estimate of $42.62 million [4] Stock Performance - Shares of AptarGroup have returned -7.3% over the past month, contrasting with the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]